Advaxis, Sellas Life Sciences deal
Advaxis granted Sellas rights to use Advaxis’ Listeria monocytogenes (LM)-based antigen delivery technology to develop Sellas’ cancer immunotherapeutic galinpepimut-S. Advaxis will conduct preclinical trials of the combination, and Sellas will be responsible for clinical development and commercialization. Advaxis is eligible for up to $358 million in milestones, plus single- to low-double-digit royalties. ...
BCIQ Target Profiles